Akebia Therapeutics Inc. buy Piper Sandler
Start price
31.05.23
/
50%
€0.92
Target price
31.05.24
-
Performance (%)
13.76%
End price
01.06.24
€1.05
Summary
This prediction ended on 01.06.24 with a price of €1.05. The BUY prediction by Piper_Sandler finished with a performance of 13.76%. Piper_Sandler has a follow-up prediction for Akebia Therapeutics Inc. where he still thinks Akebia Therapeutics Inc. is a Buy. Piper_Sandler has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Akebia Therapeutics Inc. | -0.266% | -0.266% | -71.776% | -35.216% |
| iShares Core DAX® | -1.586% | 5.028% | 6.332% | 64.061% |
| iShares Nasdaq 100 | -4.148% | -0.125% | 25.735% | 86.918% |
| iShares Nikkei 225® | -6.302% | 0.528% | 41.384% | 77.872% |
| iShares S&P 500 | -3.225% | 0.470% | 20.449% | 68.192% |
Comments by Piper_Sandler for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating.
Ratings data for AKBA provided by MarketBeat
In the thread Trading Akebia Therapeutics Inc.
Die von Piper_Sandler gewählte maximale Laufzeit wurde überschritten
Current prediction by Piper_Sandler for Akebia Therapeutics Inc.
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.29
06.02.26
06.02.26
€3.39
06.02.27
06.02.27
-38.90%
20.08.26
20.08.26
Stopped prediction by Piper_Sandler for Akebia Therapeutics Inc.
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.97
14.03.25
14.03.25
€5.53
14.03.26
14.03.26
-34.31%
15.03.26
15.03.26